Hikari Power’s Acadia Pharmaceuticals ACAD Stock Holding History

Hikari Power’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-18,535	Closed	-$495K	–	117
2019 Q2	$495K	Sell	18,535 -1,465	-7%	-$37.4K	0.05%	73
2019 Q1	$537K	Hold	20,000	–	–	0.06%	69
2018 Q4	$323K	Buy	+20,000	New	+$388K	0.04%	80
2018 Q3	–	Sell	-60,000	Closed	-$916K	–	128
2018 Q2	$916K	Buy	60,000 +20,000	+50%	+$357K	0.1%	67
2018 Q1	$899K	Hold	40,000	–	–	0.11%	64
2017 Q4	$1.2M	Hold	40,000	–	–	0.14%	56
2017 Q3	$1.51M	Sell	40,000 -20,000	-33%	-$651K	0.19%	49
2017 Q2	$1.67M	Hold	60,000	–	–	0.23%	44
2017 Q1	$2.06M	Hold	60,000	–	–	0.29%	37
2016 Q4	$1.73M	Buy	+60,000	New	+$1.59M	0.25%	40

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Hikari Power's ACAD Position: Q3 2019 in Review

Hikari Power sold out of Acadia Pharmaceuticals (ACAD) in Q3 2019, closing a stake of 18,535 shares — an estimated $495K sold.

Hikari Power first reported a position in ACAD in Q4 2016 and held it in 10 quarters. The position peaked at $2.06M in Q1 2017. 231 funds tracked by Wall St. Rank hold ACAD as of Q3 2019.

Hikari Power reported no remaining Acadia Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Hikari Power sold 18,535 Acadia Pharmaceuticals shares in Q3 2019, an estimated $495K.
Hikari Power first reported a position in Acadia Pharmaceuticals in Q4 2016 and held it in 10 quarters.
Hikari Power's Acadia Pharmaceuticals position peaked at $2.06M in Q1 2017.
231 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2019.

Based on Hikari Power's 13F filing for Q3 2019, filed 31 Oct 2019.